SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lakshi M. Aldredge, Melodie S. Young, Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy, Journal of the Dermatology Nurses’ Association, 2016, 8, 1, 14

    CrossRef

  2. 2
    Sabela Paradela, Rosa Fernández-Torres, Walter Martínez-Gómez, Eduardo Fonseca, Apremilast en dermatología, Piel, 2015,

    CrossRef

  3. 3
    Gulen Hatemi, Melike Melikoglu, Recep Tunc, Cengiz Korkmaz, Banu Turgut Ozturk, Cem Mat, Peter A. Merkel, Kenneth T. Calamia, Ziqi Liu, Lilia Pineda, Randall M. Stevens, Hasan Yazici, Yusuf Yazici, Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study, New England Journal of Medicine, 2015, 372, 16, 1510

    CrossRef

  4. 4
    Hunar Abdulrahim, Samuel Thistleton, Adewale O Adebajo, Tim Shaw, Christopher Edwards, Alvin Wells, Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis, Expert Opinion on Pharmacotherapy, 2015, 16, 7, 1099

    CrossRef

  5. 5
    Emma D. Deeks, Apremilast: A Review in Psoriasis and Psoriatic Arthritis, Drugs, 2015, 75, 12, 1393

    CrossRef

  6. 6
    Renata Baronaite Hansen, Arthur Kavanaugh, Certolizumab pegol for the treatment of psoriatic arthritis, Expert Review of Clinical Immunology, 2015, 11, 3, 307

    CrossRef

  7. 7
    Tahmina Mahmood, Daniel Zaghi, Alan Menter, Emerging oral drugs for psoriasis, Expert Opinion on Emerging Drugs, 2015, 20, 2, 209

    CrossRef

  8. 8
    Małgorzata Mazur, Jacek Karczewski, Martha Lodyga, Ryszard Żaba, Zygmunt Adamski, Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis, Journal of Dermatological Treatment, 2015, 26, 4, 326

    CrossRef

  9. 9
    Wolf-Henning Boehncke, Michael P Schön, Psoriasis, The Lancet, 2015, 386, 9997, 983

    CrossRef

  10. 10
    Suzanne J. Tintle, Alice B. Gottlieb, Psoriatic Arthritis for the Dermatologist, Dermatologic Clinics, 2015, 33, 1, 127

    CrossRef

  11. 11
    Fuminori Ohba, Maiko Nomoto, Seiichiro Hojo, Hideto Akama, Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis, Journal of Dermatological Treatment, 2015, 1

    CrossRef

  12. 12
    Melinda Gooderham, Kim Papp, Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast, BioDrugs, 2015, 29, 5, 327

    CrossRef

  13. 13
    Dennis Cada, Kyle Ingram, Danial Baker, Apremilast, Hospital Pharmacy, 2014, 49, 8, 752

    CrossRef

  14. 14
    Raewyn M. Poole, Anita D. Ballantyne, Apremilast: First Global Approval, Drugs, 2014, 74, 7, 825

    CrossRef

  15. 15
    Benjamin H Kaffenberger, Grace L Lee, Kelly Tyler, Derek V Chan, Wael Jarjour, Maria E Ariza, Marshall V Williams, Henry K Wong, Current and potential immune therapies and vaccines in the management of psoriasis, Human Vaccines & Immunotherapeutics, 2014, 10, 4, 876

    CrossRef

  16. 16
    Peter C. M. van de Kerkhof, Dermatology: Where are We Coming from and Where are We Going to?, Frontiers in Medicine, 2014, 1,

    CrossRef

  17. 17
    Renata Baronaite Hansen, Arthur Kavanaugh, Novel Treatments with Small Molecules in Psoriatic Arthritis, Current Rheumatology Reports, 2014, 16, 9

    CrossRef

  18. 18
    Laura F. Sandoval, Allison Pierce, Steven R. Feldman, Systemic Therapies for Psoriasis: An Evidence-Based Update, American Journal of Clinical Dermatology, 2014, 15, 3, 165

    CrossRef

  19. 19
    Renata Baronaite Hansen, Arthur Kavanaugh, Treatment options for psoriatic arthritis, Expert Opinion on Orphan Drugs, 2014, 2, 7, 695

    CrossRef